Clinical trials: Myeloma, Multiple
Multiple Myeloma and Plasma Cell Neoplasm
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00477971
- Testing
- filgrastim, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Mayo Clinic
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
This randomized phase II trial studies how well pomalidomide and dexamethasone work compared to lenalidomide and dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement (relapsed)…
- Trial name
- NCT01794039
- Testing
- Dexamethasone, Lenalidomide, Pomalidomide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00040937
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 141 sites in United States
- Volunteers
- 147 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma, Non-Hodgkin Lymphoma
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT02104427
- Testing
- TG-0054 combined with G-CSF
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- GPCR Therapeutics, Inc.
Multiple Myeloma
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
The purpose of the study is to determine whether the combination of LDE225 (sonidegib) plus bortezomib is safe and effective in the treatment of relapsed or relapsed/refractory multiple myeloma.
- Trial name
- NCT02254551
- Testing
- LDE225, Bortezomib
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- SCRI Development Innovations, LLC
Cancer, Myeloma
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
OBJECTIVES Primary: To evaluate the bone anabolic effect of bortezomib in patients with smoldering myeloma. Secondary: To evaluate the effect of bortezomib on the natural history of smoldering myeloma.
- Conditions
- Cancer, Myeloma, Multiple Myeloma
- Trial name
- NCT00983346
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Plasma Cell Myeloma
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant.
- Trial name
- NCT02880228
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone
The purpose of this study is to assess the safety and tolerability of Elotuzumab when given in combination with Lenalidomide and low-dose Dexamethasone in subjects with relapsed or refractory multiple myeloma (MM) in Japan.
- Trial name
- NCT01241292
- Testing
- BMS-901608 (Elotuzumab) 10 mg, BMS-901608 (Elotuzumab) 20 mg
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
The combination lenalidomide plus low-dose dexamethasone (Rd) is an active treatment for Multiple Myeloma (MM) patients, both at diagnosis and at relapse.
- Trial name
- PO-3887 (NCT03440411)
- Testing
- Pomalidomide, Cyclophosphamide, Dexamethasone
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
The primary purpose of this clinical study is to determine the recommended clinical doses of vorinostat (MK-0683) and bortezomib administered in combination to participants with relapsed and/or refractory multiple myeloma (MM).
- Trial name
- NCT00858234
- Testing
- Vorinostat, Bortezomib
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed and/or Refractory Multiple Myeloma
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK) of ixazomib alone or in combination with lenalidomide and dexamethasone (Rd), and antitumor activity of ixazomib in participants with RRMM.
- Trial name
- NCT04272775
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Volunteers
- 14 people
- Sponsor
- Takeda
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of leflunomide in treating patients with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory).
- Trial name
- NCT02509052
- Testing
- Laboratory Biomarker Analysis, Leflunomide, Pharmacological Study
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
This study is a single-center, open-label study of high-dose Melphalan HCl (hydrochloric acid) for injection (propylene glycol-free Melphalan) conducted in 24 patients, who have symptomatic multiple myeloma and qualify for…
- Trial name
- NCT02669615
- Testing
- Melphalan HCl for injection (propylene glycol free)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medical College of Wisconsin
Relapse/Refractory Multiple Myeloma
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with…
- Trial name
- MARCH (NCT03944057)
- Testing
- ATG-010
- Where
- 17 sites in China
- Volunteers
- 82 people
- Sponsor
- Antengene Corporation
Multiple Myeloma
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses…
- Trial name
- NCT00577512
- Testing
- DTPACE
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Arkansas
Multiple Myeloma
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
The goal of this proposal is to develop a more effective and better tolerated regimen. Ixazomib appears to have greater activity than bortezomib with less peripheral neuropathy.
- Trial name
- NCT02412228
- Testing
- Ixazomib, Cyclophosphamide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- John L. Reagan
Fatigue, Multiple Myeloma
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma.
- Trial name
- NCT01160380
- Testing
- armodafinil
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Oncotherapeutics
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to engraft.
- Conditions
- Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT02556931
- Testing
- Fludarabine, Cyclophosphamide, Total body irradiation
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Graft Versus Host Disease, Leukemia
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003270
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies how well busulfan, melphalan, and bortezomib before first-line stem cell transplant works in treating patients with multiple myeloma.
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01605032
- Testing
- Busulfan, Melphalan, Bortezomib
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Albert Einstein College of Medicine